This improvement was obtained in a patient population. The reversibility ETA-receptor t have on the poor. Zus Tzlich to have been less severe exacerbations in patients with moderate roflumilast observed in the placebo group, but this reduction does not reach significance. The heterogeneity t COPD need for the development of new therapies such as various medications . Therefore it has been proposed that certain subgroups of patients with COPD tend of anti-inflammatory effect of roflumilast than others. To improve for better amplification Ndnis the effects of roflumilast on exacerbations of COPD and to investigate patient groups k Nnte most of roflumilast, was a post hoc pooled analysis of 12 studies 2 months replica. This analysis showed a 14.3% reduction in the rate of severe exacerbations with roflumilast moderateto compared to placebo.

He was also able to identify subgroups of patients who showed the delicate green biggest advantage with roflumilast: Scores patients with chronic bronchitis or cough or sputum in the week before randomization and patients receiving concomitant ICS or Samas. The favorable effect of roflumilast in certain patient populations schl gt before, Required a tailored approach to optimize the treatment of COPD. This analysis of the design sp Lower clinical trials have consistently shown the efficacy of roflumilast, facilitates, identified groups of patients. Recent studies two journals, the studies that used for 12 months to receive information from the pooled analysis to investigate the effects of roflumilast in a population of patients with a background of chronic bronchitis are followed st Stronger emotion Hrdet exacerbations.
Both studies randomized, double-blind studies comparing roflumilast 500 mg once were t Resembled placebo and were designed for further study of the effects of roflumilast on lung function and the exacerbation rate. Severe COPD patients were heavy and had to submit symptom My bronchitis and a history of exacerbations. ICS were w While the study is not allowed, but BALA or Samas used Nnten k. After pre-bronchodilator FEV1 improved significantly as a treatment with roflumilast with a significant reduction of the j Hrlichen rate of exacerbations was associated. In a pooled analysis, the average rate of moderate or severe exacerbations per patient per year was 1.14 with roflumilast and 1.37 for placebo.
The most effective treatment for patients with pharmacological moderate to severe COPD who is regularly Owned long-term use of inhaled bronchodilators with ICS in patients with severe disease, the risk of exacerbations are combined. Roflumilast is as an antiinflammatory agent pleased t as a bronchodilator, it must, in combination with other therapies, including normal bronchodilators are long used. Therefore, two new studies 6 months were considered the effects of roflumilast on bronchodilator FEV1 before, when used in combination with salmeterol or tiotropium. These studies were multicenter, double-blind, randomized, parallel-group study, patients with moderate to severe COPD.